NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 11 04:00PM ET
14.71
Dollar change
-0.47
Percentage change
-3.10
%
Index- P/E6.32 EPS (ttm)2.33 Insider Own16.22% Shs Outstand69.56M Perf Week-2.97%
Market Cap1.02B Forward P/E8.11 EPS next Y1.81 Insider Trans0.00% Shs Float58.28M Perf Month1.03%
Enterprise Value515.88M PEG1.50 EPS next Q0.41 Inst Own62.49% Short Float6.48% Perf Quarter-4.85%
Income175.78M P/S2.61 EPS this Y-7.27% Inst Trans2.21% Short Ratio2.61 Perf Half Y-15.46%
Sales392.41M P/B1.65 EPS next Y11.18% ROA22.02% Short Interest3.78M Perf YTD-11.92%
Book/sh8.91 P/C1.99 EPS next 5Y4.22% ROE24.50% 52W High19.85 -25.89% Perf Year-14.33%
Cash/sh7.37 P/FCF8.39 EPS past 3/5Y3.55% 16.55% ROIC28.12% 52W Low13.14 11.95% Perf 3Y-36.04%
Dividend Est.- EV/EBITDA4.66 Sales past 3/5Y3.36% 20.35% Gross Margin80.03% Volatility3.92% 3.42% Perf 5Y-2.97%
Dividend TTM- EV/Sales1.31 EPS Y/Y TTM9.26% Oper. Margin28.05% ATR (14)0.52 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.86 Sales Y/Y TTM-15.84% Profit Margin44.80% RSI (14)52.25 Recom2.86
Dividend Gr. 3/5Y- - Current Ratio8.73 EPS Q/Q-5.48% SMA202.95% Beta1.94 Target Price17.05
Payout0.00% Debt/Eq0.01 Sales Q/Q-9.92% SMA502.10% Rel Volume0.67 Prev Close15.18
Employees599 LT Debt/Eq0.01 EarningsJul 30 BMO SMA200-12.10% Avg Volume1.45M Price14.71
IPOAug 08, 2019 Option/ShortYes / Yes EPS/Sales Surpr.-12.33% 0.45% Trades Volume971,025 Change-3.10%
Date Action Analyst Rating Change Price Target Change
Apr-29-25Downgrade BTIG Research Buy → Neutral
Apr-28-25Downgrade Robert W. Baird Outperform → Neutral $22 → $16
Oct-17-24Initiated BTIG Research Buy $25
Jul-23-24Downgrade Jefferies Buy → Hold $21 → $19
Nov-03-23Downgrade UBS Buy → Neutral $52 → $24
Oct-13-23Downgrade Canaccord Genuity Buy → Hold $55 → $22
Mar-29-23Initiated UBS Buy $40
Feb-17-23Downgrade Needham Buy → Hold
Dec-21-22Initiated Barclays Overweight $44
Oct-12-22Initiated Jefferies Buy $40
Jul-10-25 07:00AM
May-28-25 08:30AM
May-23-25 10:26AM
May-20-25 09:19AM
May-09-25 08:22AM
08:30AM Loading…
May-07-25 08:30AM
May-06-25 08:03AM
Apr-29-25 07:00AM
05:57AM
03:02AM
01:52AM
Apr-28-25 11:53AM
08:25AM
07:25AM
07:00AM
10:01AM Loading…
Apr-24-25 10:01AM
Apr-21-25 10:00AM
Apr-14-25 07:00AM
Apr-10-25 11:36AM
Apr-03-25 04:26AM
Mar-27-25 05:00AM
Mar-26-25 11:44AM
08:30AM
Mar-25-25 09:40AM
Mar-06-25 07:30AM
Mar-03-25 08:30AM
Feb-06-25 06:00PM
Feb-05-25 07:10AM
02:08AM
Feb-04-25 07:16AM
07:00AM Loading…
07:00AM
Feb-03-25 08:30AM
Jan-29-25 09:48AM
Jan-16-25 07:00AM
Jan-15-25 08:05AM
Jan-08-25 07:00AM
07:00AM
Dec-10-24 10:53PM
Nov-06-24 08:30AM
Oct-31-24 07:29AM
03:07AM
01:25AM
Oct-30-24 03:45PM
08:10AM
07:07AM
07:00AM
Oct-29-24 09:11AM
Oct-24-24 07:03AM
Oct-23-24 10:01AM
Oct-14-24 09:40AM
Oct-13-24 05:25PM
Oct-10-24 07:00AM
Oct-09-24 03:42PM
Oct-02-24 07:28AM
Oct-01-24 07:00AM
Sep-26-24 09:40AM
Sep-23-24 05:34AM
Sep-10-24 09:40AM
07:00AM
Sep-04-24 08:30AM
Sep-01-24 11:27PM
Aug-14-24 11:05AM
Aug-09-24 06:46AM
Aug-06-24 08:30AM
Aug-01-24 10:30PM
08:15AM
07:14AM
07:00AM
Jul-31-24 08:03AM
Jul-25-24 10:02AM
08:15AM
Jul-17-24 08:03AM
Jul-11-24 08:30AM
Jul-01-24 06:00AM
May-16-24 08:00AM
May-08-24 08:03AM
May-03-24 12:12PM
11:41AM
May-02-24 07:15PM
01:31PM
11:55AM
09:30AM
08:30AM
07:00AM
Apr-25-24 10:01AM
Apr-15-24 07:00AM
05:45AM
Apr-10-24 05:45AM
Apr-09-24 07:00AM
Apr-03-24 06:00PM
08:00AM
Apr-01-24 09:30AM
09:00AM
05:45AM
Mar-28-24 06:00PM
Mar-26-24 08:02AM
Mar-21-24 06:00PM
Mar-19-24 09:00AM
Mar-15-24 05:50PM
09:30AM
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.